INTERVENTION 1:	Intervention	0
Sorafenib and Ixabepilone	Intervention	1
sorafenib	CHEBI:50924	0-9
ixabepilone	CHEBI:63605	14-25
Oral targeted therapy and Systemic Chemotherapy	Intervention	2
Inclusion Criteria:	Eligibility	0
Age  18 years.	Eligibility	1
age	PATO:0000011	0-3
Histologically or cytologically confirmed breast cancer diagnosis	Eligibility	2
breast cancer	DOID:1612	42-55
with metastatic disease. Patients without pathologic or cytologic	Eligibility	3
disease	DOID:4,OGMS:0000031	16-23
confirmation of metastatic disease should have unequivocal	Eligibility	4
disease	DOID:4,OGMS:0000031	27-34
evidence of metastasis.	Eligibility	5
3. Measurable disease, as per RECIST criteria (Therasse et al.	Eligibility	6
disease	DOID:4,OGMS:0000031	14-21
2000). Measurable disease cannot be previously irradiated	Eligibility	7
disease	DOID:4,OGMS:0000031	18-25
unless progression was documented. Measurable disease is	Eligibility	8
disease	DOID:4,OGMS:0000031	46-53
defined as: at least one lesion that can be accurately measured in	Eligibility	9
at least one dimension [longest diameter to be recorded] as	Eligibility	10
diameter	PATO:0001334	32-40
>20 mm with conventional techniques, or as >10 mm with spiral	Eligibility	11
computed tomography (CT) scan. Disease must be measurable,	Eligibility	12
tomography	BAO:0002525	9-19
ct	BAO:0002125	21-23
disease	DOID:4,OGMS:0000031	31-38
i.e., bone-only disease or evaluable-only disease is not eligible.	Eligibility	13
disease	DOID:4,OGMS:0000031	16-23
disease	DOID:4,OGMS:0000031	42-49
4. Patients with brain metastasis may participate if they:	Eligibility	14
brain	UBERON:0000955	17-22
have undergone appropriate treatment,	Eligibility	15
are at least 1 month post-treatment,	Eligibility	16
month	UO:0000035	15-20
have no neurologic symptoms,	Eligibility	17
are not on steroids,	Eligibility	18
have a follow-up magnetic resonance imaging (MRI) scan that	Eligibility	19
demonstrates no residual active lesions, and	Eligibility	20
active	PATO:0002354	25-31
have no new untreated lesions.	Eligibility	21
5 The following prior therapies are allowed:	Eligibility	22
No prior chemotherapy in the metastatic setting. However,	Eligibility	23
patients must have received prior adjuvant or neo-adjuvant	Eligibility	24
adjuvant	CHEBI:60809	34-42
adjuvant	CHEBI:60809	50-58
chemotherapy.	Eligibility	25
Prior radiation therapy in either the metastatic or early-stage	Eligibility	26
setting, as long as <25% of the bone marrow has been	Eligibility	27
bone marrow	UBERON:0002371	32-43
treated. Radiation therapy must be completed at least	Eligibility	28
14 days prior to study registration, and all radiation-related	Eligibility	29
toxicities must be resolved to  grade 1 before the patient is	Eligibility	30
patient	HADO:0000008,OAE:0001817	51-58
eligible for study inclusion.	Eligibility	31
Any number of hormonal therapies in the neo-adjuvant,	Eligibility	32
adjuvant, or metastatic setting is allowed. Patients must	Eligibility	33
adjuvant	CHEBI:60809	0-8
discontinue hormonal therapy at least 1 week prior to starting	Eligibility	34
week	UO:0000034	40-44
study treatment.	Eligibility	35
Prior bevacizumab administered >4 weeks before initiation of	Eligibility	36
study treatment is allowed.	Eligibility	37
6 HER2-negative status. Documentation of HER2 results must be	Eligibility	38
available at the time of study enrollment. HER2-negative is	Eligibility	39
time	PATO:0000165	17-21
defined as:	Eligibility	40
Immunohistochemical (IHC) 0 or IHC 1+ OR	Eligibility	41
Fluorescence in situ hybridization (FISH) negative (defined by	Eligibility	42
FISH ratio <2.2) OR	Eligibility	43
ratio	UO:0000190	5-10
Silver in-situ hybridization (SISH) negative (defined by SISH	Eligibility	44
ratio <2.2).	Eligibility	45
ratio	UO:0000190	0-5
Patients with an IHC 2+ will need to be validated as HER2-negative	Eligibility	46
by FISH.	Eligibility	47
7 An Eastern Cooperative Oncology Group (ECOG) performance	Eligibility	48
group	CHEBI:24433	34-39
status of < or = to 2.	Eligibility	49
8. Normal bone marrow function as defined by:	Eligibility	50
bone marrow	UBERON:0002371	10-21
function	BAO:0003117,BFO:0000034	22-30
absolute neutrophil count (ANC) >1,500/μL;	Eligibility	51
platelets >100,000/μL;	Eligibility	52
hemoglobin >9 g/dL.	Eligibility	53
hemoglobin	CHEBI:35143	0-10
9 Normal hepatic function as defined by:	Eligibility	54
function	BAO:0003117,BFO:0000034	17-25
total bilirubin within normal institutional limits;	Eligibility	55
aspartate aminotransferase (AST) and alanine	Eligibility	56
aspartate	CHEBI:29995	0-9
alanine	CHEBI:16449	37-44
aminotransferase (ALT) <2.5 × the institutional upper limit of	Eligibility	57
normal (ULN) for patients without liver metastasis; <5.0 × ULN	Eligibility	58
liver	UBERON:0002107	34-39
for patients with liver metastasis.	Eligibility	59
liver	UBERON:0002107	18-23
10. Normal renal function as defined by creatinine <1.5 × ULN.	Eligibility	60
function	BAO:0003117,BFO:0000034	17-25
creatinine	CHEBI:16737	40-50
11. Left ventricular ejection fraction (LVEF) within institutional limits of	Eligibility	61
left	HP:0012835	4-8
ejection fraction	CMO:0000180	21-38
normal.	Eligibility	62
12. International normalized ratio (INR) <1.5 or a prothrombin	Eligibility	63
ratio	UO:0000190	29-34
prothrombin	CHEBI:8583	51-62
time/partial thromboplastin time (PT/PTT) within normal limits.	Eligibility	64
time	PATO:0000165	0-4
time	PATO:0000165	28-32
Patients receiving anti-coagulation treatment with an agent such	Eligibility	65
as warfarin or heparin may be allowed to participate. The INR	Eligibility	66
warfarin	CHEBI:10033	3-11
heparin	CHEBI:28304	15-22
should be measured prior to initiation of sorafenib, and for	Eligibility	67
sorafenib	CHEBI:50924	42-51
patients on warfarin, INR should be monitored at least weekly	Eligibility	68
warfarin	CHEBI:10033	12-20
following initiation of protocol treatment, until the INR is stable and	Eligibility	69
stable	HP:0031915	61-67
therapeutic.	Eligibility	70
13. Life expectancy of >6 months.	Eligibility	71
14. For women of childbearing potential, negative serum pregnancy	Eligibility	72
test within 7 days prior to starting treatment.	Eligibility	73
15. For women of childbearing potential and men, agreement to use a	Eligibility	74
method of contraception that is acceptable to their physician from	Eligibility	75
time of first signing the informed consent and for the study	Eligibility	76
time	PATO:0000165	0-4
duration. Men should use adequate birth control for at least three	Eligibility	77
duration	PATO:0001309	0-8
months after the last administration of sorafenib. If a woman	Eligibility	78
sorafenib	CHEBI:50924	40-49
becomes pregnant or suspects she is pregnant while participating	Eligibility	79
in this study, she must agree to inform her treating physician	Eligibility	80
immediately. As applicable, patients must agree to discontinue	Eligibility	81
breast-feeding until at least 3 weeks after their last dose of study	Eligibility	82
drug.	Eligibility	83
drug	CHEBI:23888	0-4
16. Recovery to < grade 1 toxicity due to prior therapy.	Eligibility	84
17. Ability to understand and willingness to sign a written informed	Eligibility	85
consent document.	Eligibility	86
document	IAO:0000310	8-16
Exclusion Criteria	Eligibility	87
More than one (>1) prior chemotherapy regimen.	Eligibility	88
Treatment with chemotherapy, biologic agents, or targeted agents	Eligibility	89
within the previous 4 weeks.	Eligibility	90
Previous treatment with sorafenib or ixabepilone.	Eligibility	91
sorafenib	CHEBI:50924	24-33
ixabepilone	CHEBI:63605	37-48
Women who are pregnant or breastfeeding.	Eligibility	92
Neuropathy (motor or sensory) greater than grade 1.	Eligibility	93
neuropathy	DOID:870	0-10
Uncontrolled intercurrent illness including (but not limited to)	Eligibility	94
ongoing or active infection >grade 2.	Eligibility	95
active	PATO:0002354	11-17
Known history of human immunodeficiency virus (HIV), Hepatitis	Eligibility	96
history	BFO:0000182	6-13
immunodeficiency	HP:0002721	23-39
virus	BAO:0000232	40-45
hepatitis	HP:0012115,DOID:2237	53-62
B, or Hepatitis C infection.	Eligibility	97
hepatitis c	DOID:1883	6-17
History of other non-breast cancer malignancy treated with	Eligibility	98
history	BFO:0000182	0-7
cancer	DOID:162	28-34
curative intent within the 5 years preceding study enrollment with	Eligibility	99
the exception of carcinoma in situ of the cervix, non-melanoma	Eligibility	100
carcinoma	HP:0030731,DOID:305	17-26
skin cancer, or follicular thyroid cancer.	Eligibility	101
skin cancer	DOID:4159	0-11
cancer	DOID:162	5-11
cancer	DOID:162	35-41
Concurrent hormonal therapy, chemotherapy other than	Eligibility	102
ixabepilone, or radiation treatments while on study as well as	Eligibility	103
ixabepilone	CHEBI:63605	0-11
treatment with other investigational agents while on study.	Eligibility	104
Cardiac disease:	Eligibility	105
disease	DOID:4,OGMS:0000031	8-15
Congestive heart failure (CHF) greater than New York Heart Association	Eligibility	106
congestive heart failure	HP:0001635,DOID:6000	0-24
heart	UBERON:0000948	11-16
heart	UBERON:0000948	53-58
(NYHA) Class II (see Appendix B).	Eligibility	107
Unstable angina (anginal symptoms at rest) or new onset angina	Eligibility	108
onset	HP:0003674	50-55
(i.e., began within the last 3 months).	Eligibility	109
Myocardial infarction within the past 6 months.	Eligibility	110
myocardial infarction	HP:0001658,DOID:5844	0-21
Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.	Eligibility	111
Uncontrolled hypertension (systolic blood pressure >150 mmHg	Eligibility	112
hypertension	HP:0000822,DOID:10763	13-25
systolic blood pressure	CMO:0000004	27-50
or diastolic pressure >100 mmHg despite optimal medical	Eligibility	113
management).	Eligibility	114
Thrombolic or embolic events such as cerebrovascular accident,	Eligibility	115
including transient ischemic attacks, within the past 6 months.	Eligibility	116
transient	HP:0025153	10-19
Pulmonary hemorrhage or bleeding event  grade 2 within	Eligibility	117
pulmonary hemorrhage	HP:0040223	0-20
4 weeks of the first dose of study treatment, or any other	Eligibility	118
hemorrhage or bleeding event  grade 3 within 4 weeks of the	Eligibility	119
first dose of study treatment.	Eligibility	120
14. Serious non-healing wound, ulcer, or bone fracture.	Eligibility	121
ulcer	OAE:0004372	31-36
bone fracture	HP:0020110	41-54
15. Evidence or history of bleeding diathesis or coagulopathy.	Eligibility	122
history	BFO:0000182	16-23
16. Major surgery, open biopsy or significant traumatic injury within	Eligibility	123
surgery	OAE:0000067	10-17
4 weeks of the first dose of study drugs or anticipation of the need	Eligibility	124
for major surgical procedure.	Eligibility	125
17. Chronic use of CYP3A4 inducers and use of the following strong	Eligibility	126
chronic	HP:0011010	4-11
CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin,	Eligibility	127
ketoconazole	CHEBI:47519,BAO:0000796	19-31
itraconazole	CHEBI:6076	33-45
clarithromycin	CHEBI:3732	47-61
atazanavir, nefazodone, saquinavir, telithromycin, ritonavir,	Eligibility	128
atazanavir	CHEBI:37924	0-10
nefazodone	CHEBI:7494	12-22
saquinavir	CHEBI:63621	24-34
telithromycin	CHEBI:29688	36-49
ritonavir	CHEBI:45409	51-60
amprenavir, indinavir, nelfinavir, delavirdine, and voriconazole.	Eligibility	129
amprenavir	CHEBI:40050	0-10
indinavir	CHEBI:44032	12-21
nelfinavir	CHEBI:7496	23-33
delavirdine	CHEBI:119573	35-46
voriconazole	CHEBI:10023	52-64
Use of these agents should be discontinued at least 72 hours	Eligibility	130
prior to initiation of study treatment.	Eligibility	131
18. Use of St. John's Wort or rifampin (rifampicin).	Eligibility	132
rifampicin	CHEBI:71365	40-50
19. Any condition that impairs patient's ability to swallow whole pills or	Eligibility	133
condition	PDRO:0000129	8-17
patient	HADO:0000008,OAE:0001817	31-38
gastrointestinal (GI) tract disease that involves an inability to take	Eligibility	134
disease	DOID:4,OGMS:0000031	28-35
oral medication, malabsorption syndrome, a requirement for	Eligibility	135
malabsorption	HP:0002024	17-30
syndrome	DOID:225	31-39
intravenous (IV) alimentation, prior surgical procedures affecting	Eligibility	136
absorption, or uncontrolled inflammatory GI disease (e.g., Crohn's	Eligibility	137
disease	DOID:4,OGMS:0000031	44-51
disease or ulcerative colitis).	Eligibility	138
disease	DOID:4,OGMS:0000031	0-7
ulcerative colitis	HP:0100279,DOID:8577	11-29
20. Psychiatric illness/social situations that would limit compliance	Eligibility	139
with study requirements.	Eligibility	140
21. Known or suspected allergy to sorafenib, Cremophor EL	Eligibility	141
allergy	HP:0012393	23-30
sorafenib	CHEBI:50924	34-43
(polyoxyethylated castor oil) or a drug formulated in	Eligibility	142
castor oil	CHEBI:140618	18-28
drug	CHEBI:23888	35-39
Cremophor EL such as paclitaxel or any other agent given in the	Eligibility	143
paclitaxel	CHEBI:45863	21-31
course of this trial.	Eligibility	144
Exclusion Criteria:	Eligibility	145
Outcome Measurement:	Results	0
Progression-Free Survival (PFS)	Results	1
Measured from Day 1 of study drug administration to disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) - progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions	Results	2
day	UO:0000033	14-17
drug administration	OAE:0000011	29-48
disease	DOID:4,OGMS:0000031	52-59
increase	BAO:0001251	174-182
increase	BAO:0001251	253-261
diameter	PATO:0001334	209-217
target	BAO:0003064	221-227
target	BAO:0003064	271-277
Time frame: every 9 weeks until treatment discontinuation or death on study	Results	3
time	PATO:0000165	0-4
death	OAE:0000632	61-66
Results 1:	Results	4
Arm/Group Title: Sorafenib and Ixabepilone	Results	5
sorafenib	CHEBI:50924	17-26
ixabepilone	CHEBI:63605	31-42
Arm/Group Description: Oral targeted therapy and Systemic Chemotherapy	Results	6
Overall Number of Participants Analyzed: 76	Results	7
Median (95% Confidence Interval)	Results	8
median	BAO:0002174	0-6
Unit of Measure: months  4.8        (3.5 to 6.3)	Results	9
Adverse Events 1:	Adverse Events	0
Total: 6/76 (7.89%)	Adverse Events	1
ANEMIA 1/76 (1.32%)	Adverse Events	2
anemia	HP:0001903,DOID:2355	0-6
DEATH 1/76 (1.32%)	Adverse Events	3
death	OAE:0000632	0-5
INFECTION 1/76 (1.32%)	Adverse Events	4
WEIGHT LOSS 1/76 (1.32%)	Adverse Events	5
weight loss	HP:0001824	0-11
BACK PAIN 1/76 (1.32%)	Adverse Events	6
back pain	HP:0003418	0-9
ACUTE RENAL FAILURE 1/76 (1.32%)	Adverse Events	7
acute	HP:0011009,PATO:0000389	0-5
DYSPNEA 2/76 (2.63%)	Adverse Events	8
dyspnea	HP:0002094	0-7
PNEUMONIA 1/76 (1.32%)	Adverse Events	9
pneumonia	HP:0002090,DOID:552	0-9
PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME 1/76 (1.32%)	Adverse Events	10
syndrome	DOID:225	34-42
RASH 1/76 (1.32%)	Adverse Events	11
